KDR and ovarian carcinoma: Those ovarian cancer patients with high expression of PDGFRβ and VEGFR2 might particularly benefit from additional anti-vascular therapy such as anti-VEGF antibodies or novel tyrosine kinase inhibitors targeting PDGFR and VEGFR.